AUG 13, 2021 7:30 AM PDT

Breast Cancer Drug Reverses Deadly Blood Cancer in Mice

WRITTEN BY: Annie Lennon

A drug currently used to treat advanced breast cancers may treat a rare type of leukemia known as myelofibrosis. The study was published in Cancer Research by scientists at the University of Virginia Health System. 

Myelofibrosis is a form of leukemia- cancer of the blood and bone marrow. It typically occurs in those who are middle-aged or older and affects between 1 and 1.5 in every 100,000 people. Those with advanced stages of the disease have a median survival time of 1.5 to 2.3 years. 

Ruxolitinib, a kinase inhibitor, is used to relieve symptoms of the disease. The drug, however, does not address the disease's characteristic feature, bone marrow scarring. Scarring both disrupts the marrow's production of red blood cells- causing severe anemia- and reduces the number of platelets in the blood, making clotting difficult and enlarging the spleen. 

Previous studies have found that palbociclib, a cyclin-dependent kinase (CDK) inhibitor, reduces activity in the bone marrow of patients with advanced stages of breast cancer. Researchers thus sought to see how patients with myelofibrosis would respond to the drug.

In experiments involving mouse models of myelofibrosis, the researchers showed that palbociclib was able to reduce bone marrow scarring. It also decreased excessive levels of white blood cells and shrank their enlarged spleens. 

They then found that, when combined with ruxolitinib, palbociclib was able to restore bone marrow in mice, normalize white blood cell counts, and further reduce the size of enlarged spleens. 

"A combinatorial therapeutic approach involving palbociclib and ruxolitinib will enable lowering the doses of each of the inhibitors and thus reducing toxicities while enhancing the therapeutic efficacy," wrote the researchers in their paper. 

"The findings from this study are very exciting, and they support the clinical investigation of palbociclib and ruxolitinib combination in patients with myelofibrosis," said Golam Mohi, one of the authors of the paper. 

 

Sources:  Cancer ResearchMPN ConnectScience Daily

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
NOV 08, 2021
Drug Discovery & Development
A case study of CBD's tumor shrinking potential
NOV 08, 2021
A case study of CBD's tumor shrinking potential
A recent article published in the British Medical Journal reported the case of a woman who shrank a tumor by taking CBD. ...
NOV 23, 2021
Health & Medicine
No Short Term Effects of THC-positive Breast Milk
NOV 23, 2021
No Short Term Effects of THC-positive Breast Milk
A recent study found that THC does not have short-term negative effects on an early, premature baby’s health. Rese ...
NOV 30, 2021
Immunology
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
NOV 30, 2021
Sweet Escape: A Sugar Molecule Helps HIV Remain Incognito
HIV is a master of disguise. Once the virus enters the body, it has a number of sophisticated mechanisms through which i ...
DEC 02, 2021
Cannabis Sciences
Can Cannabis Help Manage Autistic Spectrum Disorder?
DEC 02, 2021
Can Cannabis Help Manage Autistic Spectrum Disorder?
Autistic Spectrum Disorder (ASD) is a developmental disorder characterized by persistent deficits in social interaction, ...
DEC 10, 2021
Drug Discovery & Development
Blood from Physically-active Boosts Memory in Sedentary Mice
DEC 10, 2021
Blood from Physically-active Boosts Memory in Sedentary Mice
Sedentary mice experience reduced neuroinflammation and improved cognitive abilities after receiving blood from physical ...
DEC 24, 2021
Health & Medicine
Research on CBD Packaging Claims
DEC 24, 2021
Research on CBD Packaging Claims
The growth of the hemp industry has been accompanied by increased speculation about labeling accuracy of cannabidiol (CB ...
Loading Comments...